Biogen (BIIB) Prepaid Assets (2009 - 2026)
Biogen (BIIB) recorded quarterly Prepaid Assets of $1.2 billion in Q1 2026, up 4.01% quarter-over-quarter from $1.1 billion in Q4 2025, and up 54.27% on a YoY basis from $757.3 million in Q1 2025.
Biogen (BIIB) Prepaid Assets (2009 - 2026) Analysis & Trends
Biogen's Prepaid Assets history runs 18 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- In Q1 2026, Prepaid Assets rose 54.27% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 54.27% YoY), while the FY2025 annual figure was $1.1 billion, up 49.28% from the prior year.
- Prepaid Assets was $1.2 billion for Q1 2026 at Biogen, up from $1.1 billion in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $1.6 billion in Q2 2022 to a low of $615.3 million in Q2 2024.
- Historically, Prepaid Assets has averaged $1.1 billion across 5 years, with a median of $974.1 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Prepaid Assets surged 114.26% in 2022, then sank 45.55% in 2023.
- A 5-year view of Prepaid Assets shows it stood at $1.4 billion in 2022, then decreased by 16.62% to $1.2 billion in 2023, then sank by 36.34% to $752.5 million in 2024, then surged by 49.28% to $1.1 billion in 2025, then rose by 4.01% to $1.2 billion in 2026.
- The last three Prepaid Assets figures came in at $1.2 billion (Q1 2026), $1.1 billion (Q4 2025), and $916.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.17 Bn |
| Dec 31, 2025 | 1.12 Bn |
| Sep 30, 2025 | 916.80 Mn |
| Jun 30, 2025 | 850.60 Mn |
| Mar 31, 2025 | 757.30 Mn |
| Dec 31, 2024 | 752.50 Mn |
| Sep 30, 2024 | 674.00 Mn |
| Jun 30, 2024 | 615.30 Mn |
| Mar 31, 2024 | 1.17 Bn |
| Dec 31, 2023 | 1.18 Bn |
| Sep 30, 2023 | 974.10 Mn |
| Jun 30, 2023 | 895.90 Mn |
| Mar 31, 2023 | 1.41 Bn |
| Dec 31, 2022 | 1.42 Bn |
| Sep 30, 2022 | 1.50 Bn |
| Jun 30, 2022 | 1.65 Bn |
| Mar 31, 2022 | 927.40 Mn |
| Dec 31, 2021 | 740.80 Mn |
| Sep 30, 2021 | 736.30 Mn |
| Jun 30, 2021 | 767.90 Mn |